ArticleCureus2026
Recurrent Atypical Fibroxanthoma in a 76-Year-Old Man Treated With Cryotherapy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical fibroxanthoma (AFX) is a rare cutaneous neoplasm that predominantly affects elderly individuals, typically arising on sun-exposed areas of the head and neck and exhibiting diverse clinical presentations. Histologically, it is composed of atypical spindle cells and is associated with intermediate-grade malignant potential. This case report describes a 76-year-old man diagnosed with recurrent AFX, initially presenting in 2022, with subsequent recurrences in 2023 and 2024 despite adequate excisional surgeries. The patient was ultimately treated with cryotherapy, achieving a 12-month recurrence-free period. Although surgical excision remains the gold standard, there are no universally accepted standardized therapies or guidelines for AFX management. Recent studies, however, have demonstrated the efficacy of non-surgical pharmacological treatments. This report highlights the diagnostic challenges and therapeutic complexities of recurrent AFX, particularly its propensity to mimic more aggressive malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.